$4.05
2.64% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US3632252025
Symbol
GALT

Galectin Therapeutics Inc. Stock price

$4.05
-1.41 25.82% 1M
+1.88 86.64% 6M
-0.11 2.64% YTD
+2.88 246.15% 1Y
+2.92 258.41% 3Y
+1.83 82.43% 5Y
+2.43 150.00% 10Y
-14.25 77.87% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.11 2.64%
ISIN
US3632252025
Symbol
GALT
Industry

Key metrics

Basic
Market capitalization
$261.1m
Enterprise Value
$371.9m
Net debt
$110.8m
Cash
$11.5m
Shares outstanding
64.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-589.1%
Return on Equity
45.8%
ROCE
23.6%
ROIC
-
Debt/Equity
-1.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-23.1m
EBIT
$-29.1m | $-23.1m
Net Income
$-37.4m | $-32.2m
Free Cash Flow
$-30.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | 45.6%
EBIT
26.3% | 45.7%
Net Income
17.2% | 31.7%
Free Cash Flow
9.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
13.1%
Employees
15
Rev per Employee
$0.0
Show more

Is Galectin Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Galectin Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Galectin Therapeutics Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Galectin Therapeutics Inc. forecast:

Buy
86%
Hold
14%

Financial data from Galectin Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.68 5.68
3% 3%
-
- Research and Development Expense 23 23
30% 30%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -29 -29
26% 26%
-
Net Profit -37 -37
17% 17%
-

In millions USD.

Don't miss a Thing! We will send you all news about Galectin Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galectin Therapeutics Inc. Stock News

Positive
Seeking Alpha
30 days ago
Galectin Therapeutics (GALT) is building momentum on positive NAVIGATE trial data for belapectin, targeting compensated MASH cirrhosis. GALT reported a narrower Q3 loss due to lower R&D and operating expenses post-trial, with a cash runway through mid-2026 after securing a $10M credit line. Belapectin demonstrated reductions in liver stiffness, fibrogenesis, and new varices, especially in high-...
Positive
Seeking Alpha
about one month ago
Galectin Therapeutics targets MASH cirrhosis with belapectin, addressing a highly unmet need with clear mechanistic rationale and promising clinical data. GALT's NAVIGATE trial showed belapectin's 2 mg/kg dose significantly reduced disease progression and varices in high-risk patients, with consistent biomarker improvements. Despite a constrained cash runway through mid-2026 and dose-response q...
Neutral
GlobeNewsWire
about 2 months ago
NORCROSS, Ga., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three and nine months ended September 30, 2025.
More Galectin Therapeutics Inc. News

Company Profile

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease and cancer. Its programs target the development of carbohydrate molecules which offers offer alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Head office United States
CEO Joel Lewis
Employees 15
Founded 2000
Website galectintherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today